TGFB1 and ovarian carcinoma: Our previous studies [12], [15], [19], [20] and others [2], [4], [21]–[23] have tried to establish and characterize the molecular mechanisms of dysregulated TGFβ-mediated signaling in ovarian cancer cells and acquired cisplatin-resistant ovarian cancer cells.